Genetic testing giant 23andMe cuts 40% of workforce, discontinues therapeutics division
In a prepared statement, 23andMe CEO and co-founder Anne Wojcicki said the company was “taking these difficult but necessary actions” as it focuses on “the long-term success of our core consumer business and research partnerships.” RELATED ...
23andMe cuts 40% of its workforce, discontinues all therapy programs
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies in development.
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to "streamline operations and reduce costs."
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
23andMe Cuts 40 Percent Of Its Workforce And Discontinues Therapeutics Division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.The latest restructuring efforts were announced by 23andMe on Monday.
23andMe Cuts 40% of Its Workforce and Discontinues Therapeutics Division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire workforce, according to a press release Monday. The move is part of a restructuring that will see the company also halt the development of its therapeutics division which had been working on various potential medical treatments.
Rolling Out5h
23andMe cuts 40 percent of staff amid major business overhaul
This decision, described by CEO Anne Wojcicki as “difficult but necessary,” comes as the genetic testing company ...
Hosted on MSN10h
After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core ...
Black Enterprise4h
23andMe Lays Off 40% Of Employees As Company Undergoes Restructuring
Regarding its workforce reduction, which will total 200 employees, CEO Anne Wojcicki called the layoffs a “difficult but necessary” step to keep the company alive. “We are taking these difficult ...
23andMe cuts 40% of staff in restructuring
Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at ...
Business 2 Community21d
Anne Wojcicki Net Worth: 23andMe Stock Price Woes Leaves a $200 Million Fortune
American businesswoman Anne Wojcicki is the co-founder and CEO of genetic testing company 23andMe. She became a billionaire after the company went public in 2021 but since then, the company’s ...
23andMe’s entire board resigned on the same day. Founder Anne Wojcicki still thinks the startup is savable
Anne Wojcicki wanted to run things—alone. It was 2009 and her startup 23andMe was riding high, fueled by a steady stream ...
DNA-testing site 23andMe to lay off 40% of its workers
The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival.
Pittsburgh Post-Gazette on MSN6d
Nila Bala: The risks of sharing your DNA with online companies aren’t a future concern. They’re here now
DNA commodification is no longer a future concern; it’s a present reality. Beyond charging users for their services, some ...